SUMMARY AND CONCLUSION

- 1 30 cases with purulent exacerbation of chronic bronchitis- 23 males and 7 females admitted to Cairo University Hospital, were the subject of this comparative trial.

 According to a randomized list, 15 patients were treated
 with Sulphametrol + Trimethoprim "Lidaprim", and 15 patients
 were treated with Sulphamethoxazole +Trimethoprim "Septrin".

 Prior to treatment the following parameters were assessed:
 - a. Medical history including previous antibiotic treatment in the last 3 weeks.
 - b. Standard clinical examination.
 - c. Sputum bacteriological study. The susceptibility of the organisms initially isolated to Septrih and Lidaprim was studied.
 - d. Laboratory investigations: Blood picture, urine analysis, serum creatinine and serum Glutamic pyruvic transaminase level.
 - e. Estimation of forced vital capacity, forced expiratory volume in the first second and maximum voluntary ventilation.
 - f. The volume of the sputum was measured per 24 hours.

 After 10 days treatment the same parameters were restudied.

- 2 Seven different types of organisms were isolated, namely, Beta-haemolytic streptococci, staphylococcus aureus, haemophylus influenza, bacilli of the colon group, neisseria catarrhalis, diphtheroids and micrococci. The comonest pathogen isolated in the initial culture was Beta-haemolytic streptococci (66.66%): Staph aureus was isolated in 14 cases (46.66%), heamophylus influenza in 3 cases (10%). The difference of the results obtained in our country and abroad were discussed.
- 3 The invitro susceptibility of the organisms, initially cultured, to "Lidaprim" was more than that to "Septrin".
- 4 After 10 days treatment with either "Lideprim" or "Septrin" there was no emergence of resistant organisms.
- 5 The relation between in-vitro susceptibility and clinical response was studied and showed a definite correlation between both.
- 6 The comparison of the two antibacterial agents in this trial would appear to favour "Lidaprim" over "Septrin" in reducing the volume and purulence of the sputum.

 Inspite of the good clinical and bacteriological responses to both "Lidaprim" and Septrin, the various tests of lung functions (FVC, FEV, MVV) did not change signi-

ficantly .

No side effects had been detected indienting that both drugs are safe .

"Lidaprim" may therefore be regarded as a useful,
potent and safe addendum in the treatment of acute exacerbation of chronic bronchitis.